Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

agulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   ... the Simbionix RobotiX Mentor™ , a new robotic surgery ... the first time at the ERUS exhibition in ... (booth #7). Robotic-assisted minimally invasive surgery represents a ... means the needs for training for robotic surgery has increased, ...
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... Sept. 10 National Jewish Health and,Roche ... to pursue,opportunities in the growing field of ... expertise in clinical testing,and care for patients ... technology to bring new diagnostic solutions to,the ...
... September 10 Circassia Ltd, a,specialty biopharmaceutical ... announced positive results from a phase II ... the field of cat allergy.,The trial showed ... to the allergen that causes most cat ...
Cached Medicine Technology:National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities 2Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology 2Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology 3
(Date:9/18/2014)... Park City, Utah (PRWEB) September 19, 2014 ... Solution, published new information on why to switch employees ... Benefits, though many employees may be more familiar with ... individual health insurance that makes employees happier. , ... employees are happier with individual health insurance rather than ...
(Date:9/18/2014)... Mary Ann Thompson and Mathieu Nikel decided it was time to ... their son, Isaac, said there was only one choice for them ... 2001 when Thompson was an undergraduate student and needed a French ... time, was French and so she asked him. , ... when she was 7 years old. Nikel is originally from ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Active Aging ... and older as fully participating members of society and ... To celebrate, The Stafford – a boutique retirement community ... – will host two screenings of Cyber-Seniors - a ... for our residents to watch this great film,” says ...
(Date:9/18/2014)... world have issued a plea to researchers, academics, drug ... research and clinical trials for advanced breast cancer, a ... there are many unanswered questions. , In the latest ... cancer, published simultaneously in the leading cancer journals ... [1] today (Friday), the experts say that further research ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4
... Reporter , MONDAY, Dec. 5 (HealthDay News) -- Eating ... salmon, may significantly lower a young woman,s risk of ... that women of childbearing age who never ate fish had ... often, and a 90 percent higher risk than women who ...
... has seen a dramatic increase in the presence of ... the stigmatized stereotype of gays into a new, socially ... marketing strategy affects the way gays understand themselves and ... explains Wan-Hsiu Sunny Tsai, assistant professor of advertising at ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... epilepsy drug valproate have a nearly three times higher ... finds. Researchers in Denmark used national birth data ... between 1996 and 2006 to 428,000 women. Using a ...
... , MONDAY, Dec. 5 (HealthDay News) -- A ... in the teenage brain. The research found that teens who,ve ... contains brain cells -- in some areas of the brain ... involved in the study had a history of abuse or neglect. ...
... Ky. -- University of Kentucky researchers recently received a ... in Appalachia. The grant gives the team $225,000 ... additional years that could total $675,000. It is funded ... the UK-based Rural Cancer Prevention Center. Published studies ...
... Respirology reveals that dust storms have an adverse ... known as chronic obstructive pulmonary disease (COPD). Dust storms ... dust that travels long distances from North China. The concentrations ... 10 micrometerscan reach very high levels. Researchers led by ...
Cached Medicine News:Health News:Fish May Cut Threat of Heart Disease in Young Women 2Health News:Fish May Cut Threat of Heart Disease in Young Women 3Health News:How advertising shapes the image of gayness in America 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 3Health News:Abuse in Childhood May Alter Teen Brain 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: